Descartes-15
Inflammatory Bowel Disease (Ulcerative Colitis)
Key Facts
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotechnology company with a mission to expand the reach of cell therapy beyond oncology into autoimmune diseases. The company's core innovation is an mRNA cell therapy platform designed to transiently engineer patient-derived cells to produce therapeutic proteins locally at disease sites, aiming for a favorable safety and efficacy profile. Its strategy is validated by a maturing clinical pipeline, led by Descartes-08 in Phase 2b for generalized myasthenia gravis, positioning it as a public leader in this emerging therapeutic modality. Cartesian faces significant execution risks but operates in a vast and underserved market with a potentially disruptive technology.
View full company profile